Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB01059_DB01623_nanopub.RAdi__FDJM3bjoMkf6PMneP_w61y6CvchlnoD0MM0KhvE#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB01059_DB01623 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01059_DB01623 label "DDI between Norfloxacin and Thiothixene - May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. The strong CYP1A2 inhibitor, Norfloxacin, may also decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. Thorough risk:benefit assessment is required prior to co-administration. [drugbank_resource:DB01059_DB01623]" assertion.
- drugbank_resource:DB01059_DB01623 identifier "drugbank_resource:DB01059_DB01623" assertion.
- drugbank_resource:DB01059_DB01623 title "DDI between Norfloxacin and Thiothixene - May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. The strong CYP1A2 inhibitor, Norfloxacin, may also decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. Thorough risk:benefit assessment is required prior to co-administration." assertion.
- drugbank:DB01059 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01059_DB01623 assertion.
- drugbank:DB01623 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01059_DB01623 assertion.